Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H (HK:8049)

:8049

8049

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H

RESEARCH TOOLSreports

Want to see HK:8049 full AI Analyst Report?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H (8049) Price & Analysis

1 Followers

8049 Stock Chart & Stats

HK$2.16

-HK$0.03(-2.08%)

At close: Jan 09 4:00 PM EST

HK$2.16

-HK$0.03(-2.08%)

Day’s Range― - ―

52-Week RangeHK$1.70 - HK$2.60

Previous CloseN/A

Volume24.00K

Average Volume (3M)47.79K

Market Cap

HK$1.40B

Enterprise ValueHK$1.07B

Total Cash (Recent Filing)HK$748.30M

Total Debt (Recent Filing)HK$72.40M

Price to Earnings (P/E)2.9

Beta0.39

Next Earnings

Aug 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.19

Shares Outstanding172,500,000

10 Day Avg. Volume34,000

30 Day Avg. Volume47,793

Financial Highlights & Ratios

PEG Ratio0.91

Price to Book (P/B)0.65

Price to Sales (P/S)1.22

P/FCF Ratio3.65

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High ProfitabilitySustained high gross and net margins across multiple years indicate durable earnings quality and pricing power in its specialty/generic drug niche. This margin resilience supports reinvestment, internal R&D or distribution expansion and provides a buffer against cost shocks, underpinning long-term cash generation and return potential.

Conservative Balance SheetA low-leverage, equity-growing capital structure gives the company financial flexibility to fund capex, clinical development or M&A without excessive refinancing risk. Conservative liabilities lower interest burden and increase resilience to cyclical stress, supporting sustained investment in core operations and strategic optionality over months to years.

Strong Cash GenerationFree cash flow that tracks net income and recently strengthened implies high earnings quality and the ability to fund operations, capital expenditure or shareholder returns internally. Reliable cash conversion enhances balance sheet strength and strategic flexibility, enabling longer-term investments without heavy external financing.

Bears Say

Cooling Revenue GrowthAn observable slowdown and recent slight decline in top-line momentum reduces the company’s ability to scale fixed-cost leverage and may limit future margin expansion. Without renewed product launches, geographic expansion, or share gains, persistently tepid revenue risks pressuring long-term earnings growth and strategic reinvestment capacity.

Volatile Cash ConversionMaterial year-to-year swings in free cash flow complicate forecasting and capital allocation decisions. Volatility raises the risk that operational or timing factors could constrain funding for capex, R&D or debt reduction in weaker periods, making long-term planning and dividend or buyback consistency harder to sustain.

Recent Rise In DebtAn uptick in debt levels increases interest expense and reduces cushion against revenue softness. If the debt trend continues or coincides with lower revenue growth, leverage could constrain strategic moves and elevate refinancing risk over the medium term, making debt trajectory an important monitor for financial durability.

8049 FAQ

What was Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s price range in the past 12 months?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H lowest stock price was HK$1.70 and its highest was HK$2.60 in the past 12 months.

What is Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s market cap?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s market cap is HK$1.40B.

When is Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s upcoming earnings report date?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s upcoming earnings report date is Aug 13, 2026 which is in 105 days.

How were Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s earnings last quarter?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H released its earnings results on Mar 31, 2026. The company reported HK$0.187 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.187.

Is Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H overvalued?

According to Wall Street analysts Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H pay dividends?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H pays a Notavailable dividend of HK$0.273 which represents an annual dividend yield of N/A. See more information on Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H dividends here

What is Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s EPS estimate?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H have?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H has 172,500,000 shares outstanding.

What happened to Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s price movement after its last earnings report?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H reported an EPS of HK$0.187 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.304%.

Which hedge fund is a major shareholder of Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H?

Currently, no hedge funds are holding shares in HK:8049

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H

Jilin Province Huinan Changlong Bio-pharmacy Company Limited engages in the manufacture and distribution of Chinese medicines and pharmaceutical products in the People's Republic of China. It offers tablets, capsules, pills, Chinese medicine pretreatment and extraction products, powders for injections, lyophilized powder for injections, small volume injection solutions, APIs, and granules. The company markets its products under the Changlong and Qing Tong brands. The company was formerly known as Jilin Province Huinan Biochemical Pharmaceutical Company Limited. Jilin Province Huinan Changlong Bio-pharmacy Company Limited was founded in 1989 and is based in Kowloon, Hong Kong.